2025
Estimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization
Wong A, Warren J, Fitch L, Perniciaro S, Dagan R, Weinberger D. Estimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization. The Journal Of Infectious Diseases 2025, jiaf106. PMID: 40036886, DOI: 10.1093/infdis/jiaf106.Peer-Reviewed Original ResearchHigher-valent PCVsPneumococcal conjugate vaccinePneumococcal colonizationVaccine-induced serum antibodiesRisk of colonizationSerum immunoglobulin GRandomized controlled trialsConjugate vaccinePCV13Clinical trialsSerum IgGImmune responseVaccinated childrenSevere diseaseVaccine effectivenessSerum antibodiesPCV20Serotype-specificImmunoglobulin GSerotypesColonIndirect protectionIgGVaccineTrials
2024
Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
Jacobs J, Booth G, Raza S, Clark L, Fasano R, Gavriilaki E, Abels E, Binns T, Duque M, McQuilten Z, Mingot‐Castellano M, Savani B, Sharma D, Tran M, Tormey C, Moise K, Bloch E, Adkins B. Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. American Journal Of Hematology 2024, 99: 2351-2366. PMID: 39324647, PMCID: PMC11560617, DOI: 10.1002/ajh.27487.Peer-Reviewed Original ResearchHematological conditionsFcRn inhibitorsClinical trialsStandardized treatment algorithmClinical trial dataNeonatal Fc receptorIn vivo studiesImmune-mediatedHematological disordersTreatment algorithmTransports IgGAdverse eventsImmunomodulatory/immunosuppressive therapiesIgG levelsPatient populationProtective IgGFc receptorsTherapeutic strategiesMucosal surfacesRheumatologic conditionsIgG antibodiesImmunoglobulin isotypesTrial dataIgGFcRnCholera toxin and O-specific polysaccharide immune responses after oral cholera vaccination with Dukoral in different age groups of Bangladeshi participants
Dash P, Hakim A, Akter A, Banna H, Kaisar M, Aktar A, Jahan S, Ferdous J, Basher S, Kamruzzaman M, Chowdhury F, Akter A, Tauheed I, Weil A, Charles R, Calderwood S, Ryan E, LaRocque R, Harris J, Bhuiyan T, Qadri F. Cholera toxin and O-specific polysaccharide immune responses after oral cholera vaccination with Dukoral in different age groups of Bangladeshi participants. MSphere 2024, 9: e00565-23. PMID: 38391226, PMCID: PMC10964428, DOI: 10.1128/msphere.00565-23.Peer-Reviewed Original ResearchB cell responsesMemory B cell responsesClass-switched antibody responsesOral cholera vaccineAntibody responseImmune responseCholera toxin B subunitCholera vaccineToxin B subunitAge groupsAnti-OSPOlder childrenPrevent choleraIgG antibody responsesYoung childrenB subunitVaccine seriesSignificant IgAIgM responseWhole-cellOlder vaccineesCholera toxinIgAVaccineIgG
2023
Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
Zendt M, Carrillo F, Kelly S, Saturday T, DeGrange M, Ginigeme A, Wu L, Callier V, Ortega-Villa A, Faust M, Chang-Rabley E, Bugal K, Kenney H, Khil P, Youn J, Osei G, Regmi P, Anderson V, Bosticardo M, Daub J, DiMaggio T, Kreuzburg S, Pala F, Pfister J, Treat J, Ulrick J, Karkanitsa M, Kalish H, Kuhns D, Priel D, Fink D, Tsang J, Sparks R, Uzel G, Waldman M, Zerbe C, Delmonte O, Bergerson J, Das S, Freeman A, Lionakis M, Sadtler K, van Doremalen N, Munster V, Notarangelo L, Holland S, Ricotta E. Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies. Science Advances 2023, 9: eadh3150. PMID: 37824621, PMCID: PMC10569702, DOI: 10.1126/sciadv.adh3150.Peer-Reviewed Original ResearchConceptsHealthy volunteersIgG levelsDose of coronavirus diseaseImmune response to COVID-19 vaccinationResponse to COVID-19 vaccinationAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 infectionMessenger RNA-based vaccinesMedian IgG levelsOrgan transplant populationCoronavirus 2 infectionRNA-based vaccinesImmunomodulating treatmentTransplant populationDose 2Dose 3Prospective cohortCoronavirus diseaseDoseCOVID-19 vaccineOmicron BABivalent vaccineImmunoglobulin GVaccineIgGCorrelation of a commercial platform’s results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors
Slotkin R, Kyriakides T, Kundu A, Stack G, Sutton R, Gupta S. Correlation of a commercial platform’s results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors. PLOS ONE 2023, 18: e0289713. PMID: 37643190, PMCID: PMC10464955, DOI: 10.1371/journal.pone.0289713.Peer-Reviewed Original Research
2022
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
Ullah I, Beaudoin-Bussières G, Symmes K, Cloutier M, Ducas E, Tauzin A, Laumaea A, Grunst M, Dionne K, Richard J, Bégin P, Mothes W, Kumar P, Bazin R, Finzi A, Uchil P. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Reports Medicine 2022, 4: 100893. PMID: 36584683, PMCID: PMC9799175, DOI: 10.1016/j.xcrm.2022.100893.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaFc effector functionsSARS-CoV-2 controlFc effector activityInnate immune cellsCCP efficacyHACE2 miceConvalescent plasmaImmunoglobulin levelsPlasma therapyImmune cellsTreatment efficacyDelays mortalityIgG fractionFc functionLow neutralizingTherapySecond lineMortalityMicePlasma contributesEfficacyFC activityProphylaxisIgG
2021
Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection
Cravedi P, Ahearn P, Wang L, Yalamarti T, Hartzell S, Azzi Y, Menon M, Jain A, Billah M, Fernandez-Vina M, Gebel HM, Woodle ES, Haddad NS, Morrison-Porter A, Lee FE, Sanz I, Akalin E, Girnita A, Maltzman JS. Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection. Journal Of The American Society Of Nephrology 2021, 32: 3221-3230. PMID: 34599041, PMCID: PMC8638399, DOI: 10.1681/asn.2021040573.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionKidney transplant recipientsTransplant recipientsImmunocompetent controlsSARS-CoV-2 IgASARS-CoV-2 antibodiesTime pointsCross-sectional studyCOVID-19Basis of timingLater time pointsIgG1-4Transplant statusIgA antibodiesIgG responsesIgM responseImmunocompetent individualsPoor outcomeSevere outcomesViral epitopesInfectionIgGRecipientsAntibodiesClass switchingImmunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines
Wisnewski AV, Redlich CA, Liu J, Kamath K, Abad QA, Smith RF, Fazen L, Santiago R, Luna J, Martinez B, Baum-Jones E, Waitz R, Haynes WA, Shon JC. Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines. PLOS ONE 2021, 16: e0252849. PMID: 34499652, PMCID: PMC8428655, DOI: 10.1371/journal.pone.0252849.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccine recipientsLinear epitopesSARS-CoV-2 neutralizationCOVID-19 mRNA vaccinesVaccine-induced IgGMRNA vaccine recipientsSARS-CoV-2 spike proteinDominant linear epitopeElicit IgGVaccine recipientsVaccine effectivenessMRNA vaccinesVaccination samplesImmune escapeHuman coronavirusesHealthy adultsSARS-CoVVaccine epitopesCritical epitopesAdverse responsesReverse vaccinologySpike proteinNatural infectionS2 subunitIgGHuman IgG and IgA responses to COVID-19 mRNA vaccines
Wisnewski AV, Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLOS ONE 2021, 16: e0249499. PMID: 34133415, PMCID: PMC8208542, DOI: 10.1371/journal.pone.0249499.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinesAntigen-specific IgGMRNA vaccinesIgG levelsCOVID-19 mRNA vaccinationAntigen-specific IgG levelsInitial vaccine doseAntigen-specific IgASARS-CoV-2More rapid declineSecond vaccineVaccine doseMRNA vaccinationIgA responsesSerum levelsVaccine dosesSpecific IgGNatural immunityViral neutralizationIgAVaccinePeak levelsIgGVaccinationHuman IgGPvMSP8 as a Novel Plasmodium vivax Malaria Sero-Marker for the Peruvian Amazon
Villasis E, Garro K, Rosas-Aguirre A, Rodriguez P, Rosado J, Gave A, Guzman-Guzman M, Manrique P, White M, Speybroeck N, Vinetz JM, Torres K, Gamboa D. PvMSP8 as a Novel Plasmodium vivax Malaria Sero-Marker for the Peruvian Amazon. Pathogens 2021, 10: 282. PMID: 33801386, PMCID: PMC7999794, DOI: 10.3390/pathogens10030282.Peer-Reviewed Original ResearchSerological responsePopulation-based cross-sectional surveyRecent malaria exposureMerozoite surface protein 8Non-exposed individualsCross-sectional surveyMalaria control effortsTime of surveyPV exposureMalaria exposureIgG antibodiesTransmission settingsPV infectionGood biomarkerRecent exposurePast monthIgGPlasma samplesProtein 8Second evaluationExposureFirst evaluationIndividualsLuminexCohort
2018
IgG Responses to the Plasmodium falciparum Antigen VAR2CSA in Colombia Are Restricted to Pregnancy and Are Not Induced by Exposure to Plasmodium vivax
Lopez-Perez M, Larsen M, Bayarri-Olmos R, Ampomah P, Stevenson L, Arévalo-Herrera M, Herrera S, Hviid L. IgG Responses to the Plasmodium falciparum Antigen VAR2CSA in Colombia Are Restricted to Pregnancy and Are Not Induced by Exposure to Plasmodium vivax. Infection And Immunity 2018, 86: 10.1128/iai.00136-18. PMID: 29784859, PMCID: PMC6056870, DOI: 10.1128/iai.00136-18.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnimalsAntibodies, ProtozoanAntigens, ProtozoanChildChild, PreschoolColombiaFalse Positive ReactionsFemaleGlycosylationHumansImmunoassayImmunoglobulin GMalaria, FalciparumMalaria, VivaxMaleMiceMiddle AgedPregnancyPregnancy Complications, InfectiousRecombinant ProteinsYoung AdultConceptsIgG reactivityPregnant womenPfEMP1 proteinsInfected erythrocytesAcquisition of IgGPrevious malaria exposureDuffy-binding proteinErythrocyte membrane protein 1 (PfEMP1) familyPlacental parasitesClinical immunityMalaria immunityIgG responsesMalaria exposureRecombinant VAR2CSAMouse monoclonalVariant antigensColombian menIgGPlasma samplesRabbit antibodiesChinese hamster ovary cellsPregnancyVAR2CSAHamster ovary cellsMalaria
2015
Immune response to Propionibacterium acnes in patients with sarcoidosis – in vivo and in vitro
Schupp J, Tchaptchet S, Lützen N, Engelhard P, Müller-Quernheim J, Freudenberg M, Prasse A. Immune response to Propionibacterium acnes in patients with sarcoidosis – in vivo and in vitro. BMC Pulmonary Medicine 2015, 15: 75. PMID: 26204953, PMCID: PMC4513400, DOI: 10.1186/s12890-015-0070-7.Peer-Reviewed Original ResearchConceptsHeat-killed P. acnesSarcoid patientsP. acnesBAL cellsBAL fluidTotal IgGImmune responseHealthy volunteersPathogenesis of sarcoidosisSpecific antibodiesGM-CSF productionIgA titresIgA levelsLymph nodesInflammatory cytokinesGranuloma formationMore TNFSarcoidosisPatientsPropionibacterium acnesAcneGM-CSFElevated levelsAntibodiesIgG
2014
Borrelia miyamotoi sensu lato Seroreactivity and Seroprevalence in the Northeastern United States - Volume 20, Number 7—July 2014 - Emerging Infectious Diseases journal - CDC
Krause PJ, Narasimhan S, Wormser GP, Barbour AG, Platonov AE, Brancato J, Lepore T, Dardick K, Mamula M, Rollend L, Steeves TK, Diuk-Wasser M, Usmani-Brown S, Williamson P, Sarksyan DS, Fikrig E, Fish D, . Borrelia miyamotoi sensu lato Seroreactivity and Seroprevalence in the Northeastern United States - Volume 20, Number 7—July 2014 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2014, 20: 1183-1190. PMID: 24960072, PMCID: PMC4073859, DOI: 10.3201/eid2007.131587.Peer-Reviewed Original ResearchConceptsB. burgdorferiInfectious Diseases journal - CDCSeroprevalence of IgGB. burgdorferi antigensLyme disease endemic areaDisease-endemic areasAntibody testingHealthy personsLyme diseaseSerum samplesSeroprevalenceBurgdorferiInfectionSame tickUnited StatesSensu latoArea residentsPersonsBorrelia spSeroreactivityIgGAntigenDiseaseSerum
2013
Punctate pemphigus: an underreported direct immunofluorescence pattern
Ko CJ, McNiff JM. Punctate pemphigus: an underreported direct immunofluorescence pattern. Journal Of Cutaneous Pathology 2013, 41: 293-296. PMID: 24372009, DOI: 10.1111/cup.12272.Peer-Reviewed Original ResearchConceptsIntercellular depositionIntercellular IgG depositionDirect immunofluorescence studiesCases of pemphigusDirect immunofluorescence patternsDot-like patternIgG depositionPemphigus vulgarisDiagnostic findingsPemphigus foliaceusPemphigusImmunofluorescence patternImmunoglobulin GImmunofluorescence studiesPotential mechanismsIgGDIF studiesAntiphospholipid Antibodies in Stillbirth
Silver RM, Parker CB, Reddy UM, Goldenberg R, Coustan D, Dudley DJ, Saade GR, Stoll B, Koch MA, Conway D, Bukowski R, Hogue CJ, Pinar H, Moore J, Willinger M, Branch DW. Antiphospholipid Antibodies in Stillbirth. Obstetrics And Gynecology 2013, 122: 641-657. PMID: 23921873, PMCID: PMC5684877, DOI: 10.1097/aog.0b013e3182a1060e.Peer-Reviewed Original ResearchConceptsI antibodiesPopulation-based case-control studyLive-birth deliveriesOdds of stillbirthCase-control studyIgM anticardiolipinStillbirth deliveryAntiphospholipid antibodiesMaternal serumBirth deliveryLive birthsStillbirthElevated levelsAntibodiesIgGDeliveryAnticardiolipinMulticenterImmunoglobulinSerum
2010
Cross Talk Between Pathogenic CD4+T Cells and B Cells (143.35)
Xiang Y, Peng J, Tai N, Hu C, Zhou Z, Wen L. Cross Talk Between Pathogenic CD4+T Cells and B Cells (143.35). The Journal Of Immunology 2010, 184: 143.35-143.35. DOI: 10.4049/jimmunol.184.supp.143.35.Peer-Reviewed Original Research
2007
Respiratory Symptoms, Sensitization, and Exposure–Response Relationships in Spray Painters Exposed to Isocyanates
Pronk A, Preller L, Raulf-Heimsoth M, Jonkers IC, Lammers JW, Wouters IM, Doekes G, Wisnewski AV, Heederik D. Respiratory Symptoms, Sensitization, and Exposure–Response Relationships in Spray Painters Exposed to Isocyanates. American Journal Of Respiratory And Critical Care Medicine 2007, 176: 1090-1097. PMID: 17656675, PMCID: PMC2176099, DOI: 10.1164/rccm.200702-215oc.Peer-Reviewed Original ResearchConceptsWork-related chest tightnessExposure-response relationshipRespiratory symptomsChest tightnessSpecific IgESpecific IgGSpecific IgE sensitizationExposure-response associationsDisease-like symptomsTime-activity informationAsthmalike symptomsIgE sensitizationIndicator of exposureSpecific sensitizationSymptomatic individualsHSA conjugatesRespiratory diseaseSpray paintersSymptomsIgESensitizationPrevalenceIgGPersonal exposureOffice workersDiisocyanate conjugate and immunoassay characteristics influence detection of specific antibodies in HDI‐exposed workers
Campo P, Wisnewski AV, Lummus Z, Cartier A, Malo J, Boulet LP, Bernstein DI. Diisocyanate conjugate and immunoassay characteristics influence detection of specific antibodies in HDI‐exposed workers. Clinical & Experimental Allergy 2007, 37: 1095-1102. PMID: 17581205, DOI: 10.1111/j.1365-2222.2007.02745.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAir Pollutants, OccupationalAsthmaBronchial Provocation TestsCyanatesEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoassayImmunoglobulin EImmunoglobulin GInhalation ExposureIsocyanatesMaleMiddle AgedMolecular StructureObserver VariationOccupational DiseasesPredictive Value of TestsQuality ControlQuebecRadioallergosorbent TestReagent Kits, DiagnosticReproducibility of ResultsSensitivity and SpecificitySerum AlbuminSkin TestsConceptsSpecific inhalation challengeDiisocyanate asthmaSpecific IgEHuman serum albumin conjugatesSpecific antibodiesSpecific IgG antibodiesInhalation challengeAsthmatic reactionSpecific IgGHDI exposureIgG antibodiesTest antigenPredictive valueSerum albumin conjugatesAntigen immunoassayIgEProtein antigensIgG immunoassayShop workersInter-laboratory variabilityAlbumin conjugatesAntibodiesAsthmaRASTIgG
2006
Biophysical determinants of toluene diisocyanate antigenicity associated with exposure and asthma
Ye YM, Kim CW, Kim HR, Kim HM, Suh CH, Nahm DH, Park HS, Redlich CA, Wisnewski AV. Biophysical determinants of toluene diisocyanate antigenicity associated with exposure and asthma. Journal Of Allergy And Clinical Immunology 2006, 118: 885-891. PMID: 17030242, DOI: 10.1016/j.jaci.2006.06.026.Peer-Reviewed Original Research
2004
The Occurrence of Antibodies to Components of the Natural Coagulation Inhibitor System, Protein Z and Protheombin in Normal Pregnancy.
Ku D, Arkel Y, Paidas M, Triche E, Huang S, Musto J, Lockwood C. The Occurrence of Antibodies to Components of the Natural Coagulation Inhibitor System, Protein Z and Protheombin in Normal Pregnancy. Blood 2004, 104: 3995. DOI: 10.1182/blood.v104.11.3995.3995.Peer-Reviewed Original ResearchNon-pregnant controlsAnti-PC IgMAdverse pregnancy outcomesNormal pregnancyIgM antibodiesPS IgGOccurrence of antibodiesAnticardiolipin syndromeProthrombotic processesPregnancy outcomesAntibody levelsMost pregnanciesAutoimmune diseasesAntibody responseIgG antibodiesHemostatic balanceImmune responseTrimesterCoagulation factorsChronic responsesPregnancyIgMIgGGestationAntibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply